Difficulties with fungal infections in acute myelogenous leukemia patients: Immune enhancement strategies

Oncologist

Volumn 12, Issue SUPPL. 2, 2007, Pages 2-6

  Safdar, Amar ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Granulocyte macrophage colony stimulating factor interferon gamma; Immune enhancement; Invasive fungal infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; GAMMA1B INTERFERON; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VORICONAZOLE; ANTIFUNGAL AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE COMPARISON; ENZYME IMMUNOASSAY; GRANULOCYTE TRANSFUSION; HELPER CELL; HUMAN; IMMUNITY; LUNG ASPERGILLOSIS; MONOTHERAPY; MUCORMYCOSIS; MYCOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UNSPECIFIED SIDE EFFECT; MICROBIOLOGY;

ANTIFUNGAL AGENTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYCOSES;

EID: 38449101849     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-S2-2     Document Type: Review

References (23)

1. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States. 1980-1997. Clin Infect Dis 2001;33:641-647.
2. Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-547.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: Systematic review of the literature. Clin Infect Dis 2001;32:358-366.
4. Martin GS, Mannino DM, Eaton S et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
5. Lamaris GA, Chamilos G, Lewis RE et al. Scedosporium infection in a tertiary care cancer center: A review of 25 cases from 1989-2006. Clin Infect Dis 2006;43:1580-1584.
6. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hemato-poietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14.
7. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign. Clin Infect Dis 2007;44:373-379.
8. Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant 2006;38:327-337.
9. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608-615.
10. Herbrecht R, Denning DW, Patterson TF et al.; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
11. Kontoyiannis DP, Lionakis MS. Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-1360.
12. Maertens J, Raad I, Petrikkos G et al.; Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:l563-1571.
13. Aliff TB, Maslak PG, Jurcic JG et al. Refractory Aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003;97:1025-1032.
14. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003;98:292-299.
15. Marr KA, Boeckh M, Carter RA et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797-802.
16. Safdar A, Rodriguez G, Rolston KV et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;39:157-164.
17. B̈chner T. Hiddemann W, Koenigsmann M et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991;78:1190-1197.
18. Bodey GP, Anaissie E. Gutterman J et al. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis 1994;13(suppl2):S18-S22.
19. Rowe JM. Andersen J W, Mazza JJ et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457-462.
20. Rowe JM. Rubin A, Mazza JJ et al. Incidence of infections in adult patients with acute myeloid leukemia treated with yeast-derived GM-CSF (sar-gramostim): Results of a double-blind prospective study by the Eastern Cooperative Oncology Group. In: Hiddemann W, Büchner T, Wörmann B et al., eds. Acute Leukemias V: Experimental Approaches and Management of Refractory Disease. Berlin: Springer, 1996:178-184.
21. Safdar A, Rodriguez G, Ohmagari N et al. The safety of interferon-γ-lb therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer 2005;103:731-739.
22. Hübel K, Carter R A, Liles WC et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: A comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 2002;42:1414-1421.
23. Safdar A, Rodriguez GH, Lichtiger B et al. Recombinant interferon γlb immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer 2006;106:2664-2671.